Skip to main content
SpringerLink
Log in

HPV-Infektionen der Mund- und Genitalschleimhaut

Möglichkeiten der primären Prävention

HPV infections of the oral and genital mucosa

Possibilities for primary prevention

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Es gilt heute als gesichert, dass nahezu alle Fälle von Zervixkarzinomen durch persistierende Infektionen mit sog. „Hoch-Risiko“ humanen Papillomviren (HPV) verursacht werden, insbesondere durch die Typen HPV16 und HPV18 (ca. 70%). Darüber hinaus sind diese HPV-Typen auch für einen Teil anderer Karzinome wie Vulva-, Vaginal-, Anal-, Penis- und Oropharynxkarzinome verantwortlich. Diese Erkenntnis impliziert, dass man die Entwicklung dieser Karzinome unterbinden kann, wenn ein Großteil der verursachenden Infektionen verhindert werden kann.

Abstract

It is well accepted today that almost all cases of carcinoma of the cervix are caused by persistent infections with high-risk human papilloma viruses (HPV), especially through types HPV16 and HPV18 (ca. 70%). These same types are also responsible for some carcinomas of the vulva, anus, penis and oropharynx. This knowledge indicates that it should be possible to prevent these carcinomas if a majority of the causstive HPV infections can be prevented.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Handisurya A, Schellenbacher C, Kirnbauer R (2009) Diseases caused by human papillomaviruses (HPV). J Dtsch Dermatol Ges 7:453–466, quiz 466, 467

    Article  PubMed  Google Scholar 

  2. Handisurya A, Rieger A, Bago-Horvath Z et al (2009) Rapid progression of an anal Buschke-Lowenstein tumour into a metastasising squamous cell carcinoma in an HIV-infected patient. Sex Transm Infect 85:261–263

    Article  CAS  PubMed  Google Scholar 

  3. Handisurya A, Gambhira R, Schellenbacher C et al (2009) Serological relationship between cutaneous human papillomavirus types 5, 8 and 92. J Gen Virol 90:136–143

    Article  CAS  PubMed  Google Scholar 

  4. Handisurya A, Rieger A, Bankier A et al (2007) Human papillomavirus type 26 infection causing multiple invasive squamous cell carcinomas of the fingernails in an AIDS patient under highly active antiretroviral therapy. Br J Dermatol 157:788–794

    Article  CAS  PubMed  Google Scholar 

  5. Kirnbauer R, Lenz P, Okun MM (2008) Human papillomavirus. In: Bolognia J, Jorizzo J, Rapini R (eds) Dermatology. Mosby, London, pp 1183–1198

  6. Howley PM, Lowy DR (2007) Papillomavirus. In: Knipe DM, Howley PM (eds) Fields virology. Lippincott Williams and Wilkins, Philadelphia, pp 2299–2354

  7. Kirnbauer R, Booy F, Cheng N et al (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89:12180–12184

    Article  CAS  PubMed  Google Scholar 

  8. Garland SM, Hernandez-Avila M, Wheeler CM et al (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928–1943

    Article  CAS  PubMed  Google Scholar 

  9. Paavonen J, Jenkins D, Bosch FX et al (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161–2170

    Article  CAS  PubMed  Google Scholar 

  10. Schellenbacher C, Roden R, Kirnbauer R (2009) Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol 83:10085–10095

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor weist auf folgende Beziehungen hin: Reinhard Kirnbauer ist Miterfinder und Lizenzinhaber der HPV-VLP-Vakzine-Technologie. Diese wurde an die Firmen Glaxo und Merck/SanofiPasteur lizensiert, die die Vakzine kommerziell entwickeln.

Author information

Authors and Affiliations

  1. Labor für Virale Onkologie (LVO), Abteilung für Immundermatologie und infektiöse Hautkrankheiten, Klinik für Dermatologie, Medizinische Universität Wien, Allgemeines Krankenhaus, Währinger Gürtel 18–20, 1090, Wien, Österreich

    R. Kirnbauer, C. Schellenbacher, S. Shafti-Keramat & A. Handisurya

Authors
  1. R. Kirnbauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Schellenbacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. Shafti-Keramat
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Handisurya
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Kirnbauer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kirnbauer, R., Schellenbacher, C., Shafti-Keramat, S. et al. HPV-Infektionen der Mund- und Genitalschleimhaut . Hautarzt 60, 878–880 (2009). https://doi.org/10.1007/s00105-009-1803-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-009-1803-4

Schlüsselwörter

Keywords

Search

Navigation